Jinwon Life Sciences Expands Clinical Research on COVID-19 Cosprey Treatment for General Public

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science is expanding the clinical trial participants of the COVID-19 infection prevention nasal spray treatment (GLS-1200) to include the general public.

On the 15th, GeneOne Life Science announced that the Phase 2 clinical study of GLS-1200 is currently underway at the University of Pennsylvania Clinical Center in the United States, involving 128 healthcare workers, with no serious adverse events reported so far.

They also stated that the Baton Rouge Clinical Trial Center is currently undergoing the IRB amendment approval process to include not only healthcare workers but also the general public as clinical trial participants.

Park Young-geun, CEO of GeneOne Life Science, explained, "Since late last year, the supply and administration of COVID-19 vaccines in the U.S. have been focused on healthcare workers, limiting the number of healthcare workers participating in the Phase 2 clinical study of GLS-1200, which has delayed the recruitment of clinical trial participants more than expected."

CEO Park added, "Baton Rouge City in Louisiana still shows a high infection rate, and since we are expanding clinical trial participants to the general public, we are doing our best to complete the clinical trial quickly by coordinating with the clinical trial center to prevent delays in the clinical study."

This content was produced with the assistance of AI translation services.